Perhaps I greatly misunderstand.
The scoping study shows a pre-tax, pre-capital surplus of $49 million.
It also says the cost of the plant would be $66 million.
So do you not have to remove the cost of the plant for the cash surplus of $49m? Leaving 17million in the red?
That is how I understood it?
- Forums
- ASX - By Stock
- SVL
- a crucial time, worth the punt?
a crucial time, worth the punt?, page-3
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SVL (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.7¢ |
Change
-0.001(1.02%) |
Mkt cap ! $146.2M |
Open | High | Low | Value | Volume |
9.5¢ | 10.3¢ | 9.4¢ | $969.1K | 9.974M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 150000 | 9.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.8¢ | 889602 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 150000 | 0.097 |
11 | 762171 | 0.096 |
12 | 926687 | 0.095 |
9 | 980988 | 0.094 |
12 | 711089 | 0.093 |
Price($) | Vol. | No. |
---|---|---|
0.098 | 889602 | 6 |
0.099 | 538524 | 5 |
0.100 | 759349 | 7 |
0.105 | 965484 | 13 |
0.110 | 1315519 | 13 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
SVL (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online